Aldeyra Net Income From Continuing Ops Over Time
| ALDX Stock | USD 5.36 0.04 0.75% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Aldeyra Performance and Aldeyra Correlation. Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aldeyra. If investors know Aldeyra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Aldeyra assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Understanding Aldeyra requires distinguishing between market price and book value, where the latter reflects Aldeyra's accounting equity. The concept of intrinsic value—what Aldeyra's is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Aldeyra's price substantially above or below its fundamental value.
Understanding that Aldeyra's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Aldeyra represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Aldeyra's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Net Income From Continuing Ops Analysis
Compare Aldeyra and related stocks such as AC Immune, Mereo BioPharma Group, and Silence Therapeutics PLC Net Income From Continuing Ops Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ACIU | (11.2 M) | (11.2 M) | (11.2 M) | (11.2 M) | 10.8 M | 20.1 M | (7.1 M) | (26.4 M) | (51 M) | 45.4 M | (61.9 M) | (73 M) | (70.8 M) | (54.2 M) | (50.9 M) | (45.8 M) | (43.5 M) |
| MREO | (480 M) | (480 M) | (480 M) | (480 M) | (480 M) | (480 M) | (28.4 M) | (38.8 M) | (32 M) | (34.8 M) | (163.6 M) | 12.7 M | (34.2 M) | (29.5 M) | (43.3 M) | (49.7 M) | (52.2 M) |
| SLN | (8.4 M) | (8.4 M) | (8.4 M) | (8.4 M) | (8.4 M) | (8.4 M) | (8.4 M) | (1.6 M) | (18.4 M) | (19.6 M) | (22.1 M) | (39.4 M) | (40.5 M) | (43.3 M) | (45.3 M) | (40.8 M) | (42.8 M) |
| CLLS | (26.8 M) | (26.8 M) | (26.8 M) | (26.8 M) | 1.9 M | (22.6 M) | (63.9 M) | (103.7 M) | (88.3 M) | (115.2 M) | (97.5 M) | (125.1 M) | (98.7 M) | (116.8 M) | (36.8 M) | (33.1 M) | (34.7 M) |
| GNLX | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (16.4 M) | (5.2 M) | (25 M) | (29.9 M) | (26.9 M) | (28.2 M) |
| CTNM | (29 M) | (29 M) | (29 M) | (29 M) | (29 M) | (29 M) | (29 M) | (29 M) | (29 M) | (29 M) | (29 M) | (29 M) | (24.3 M) | 22.7 M | (42.3 M) | (48.6 M) | (46.2 M) |
| ANRO | (9.2 M) | (9.2 M) | (9.2 M) | (9.2 M) | (9.2 M) | (9.2 M) | (9.2 M) | (9.2 M) | (9.2 M) | (9.2 M) | (9.2 M) | (27.7 M) | (36.3 M) | (61.4 M) | (61.4 M) | (55.3 M) | (52.5 M) |
| AMRN | (166.2 M) | (166.2 M) | (166.2 M) | (166.2 M) | (56.4 M) | (115.2 M) | (86.3 M) | (67.9 M) | (116.4 M) | (22.6 M) | (18 M) | 7.7 M | (105.8 M) | (52.5 M) | (82.2 M) | (94.5 M) | (99.2 M) |
| CADL | (8.2 M) | (8.2 M) | (8.2 M) | (8.2 M) | (8.2 M) | (8.2 M) | (8.2 M) | (8.2 M) | (8.2 M) | (8.2 M) | (17.7 M) | (36.1 M) | (18.8 M) | (31.9 M) | (55.2 M) | (49.7 M) | (47.2 M) |
| KYTX | (26.4 M) | (26.4 M) | (26.4 M) | (26.4 M) | (26.4 M) | (26.4 M) | (26.4 M) | (26.4 M) | (26.4 M) | (26.4 M) | (26.4 M) | (26.4 M) | (28.9 M) | (60.4 M) | (127.5 M) | (114.7 M) | (109 M) |
Aldeyra and related stocks such as AC Immune, Mereo BioPharma Group, and Silence Therapeutics PLC Net Income From Continuing Ops description
My Equities
My Current Equities and Potential Positions
| Aldeyra | ALDX |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 131 Hartwell Avenue, |
| Exchange | NASDAQ Exchange |
USD 5.36
Additional Tools for Aldeyra Stock Analysis
When running Aldeyra's price analysis, check to measure Aldeyra's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aldeyra is operating at the current time. Most of Aldeyra's value examination focuses on studying past and present price action to predict the probability of Aldeyra's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aldeyra's price. Additionally, you may evaluate how the addition of Aldeyra to your portfolios can decrease your overall portfolio volatility.